NKGen Biotech, Inc.

NKGen Biotech, Inc. (Nasdaq: NKGN) is a clinical-stage biopharmaceutical company focused on natural killer cell-based therapies, with lead programs targeting Alzheimer's disease and oncology indications. The company went public through a business combination with Graf Acquisition Corp. IV, a blank-check vehicle sponsored by Graf Holdings LLC that completed its IPO in 2021 with a healthcare sector focus. Following the merger close, NKGen began trading under the NKGN ticker on Nasdaq and filed its Form 10-K annual report with the SEC on March 31, 2023. As of that filing, the company held no approved products and remained in the clinical development stage. Sign up at SpacDesk for full data on NKGN and thousands of other SPAC transactions.